scholarly journals Gallic Acid Inhibits Invasion and Reduces IL-6 Gene Expression, pSTAT3, pERK1/2, and pAKT Cellular Signaling Proteins in Human Prostate Cancer DU-145 Cells

2017 ◽  
Vol 10 (11) ◽  
Author(s):  
Esfandiar Heidarian ◽  
Mahnaz Keloushadi ◽  
Keihan Ghatreh-Samani ◽  
Effat Jafari-Dehkordi
2011 ◽  
Vol 28 (10) ◽  
pp. 579-587 ◽  
Author(s):  
Kuo-Ching Liu ◽  
Heng-Chien Ho ◽  
An-Cheng Huang ◽  
Bin-Chuan Ji ◽  
Hui-Yi Lin ◽  
...  

2007 ◽  
Vol 58 (2) ◽  
pp. 197-204 ◽  
Author(s):  
Merrill J. Christensen ◽  
Edward T. Nartey ◽  
Aimee L. Hada ◽  
Russell L. Legg ◽  
Brett R. Barzee

2021 ◽  
Vol 12 ◽  
Author(s):  
Taraswi Mitra Ghosh ◽  
Jason White ◽  
Joshua Davis ◽  
Suman Mazumder ◽  
Teeratas Kansom ◽  
...  

Repetitive, low-dose (metronomic; METRO) drug administration of some anticancer agents can overcome drug resistance and increase drug efficacy in many cancers, but the mechanisms are not understood fully. Previously, we showed that METRO dosing of topotecan (TOPO) is more effective than conventional (CONV) dosing in aggressive human prostate cancer (PCa) cell lines and in mouse tumor xenograft models. To gain mechanistic insights into METRO-TOPO activity, in this study we determined the effect of METRO- and CONV-TOPO treatment in a panel of human PCa cell lines representing castration-sensitive/resistant, androgen receptor (+/−), and those of different ethnicity on cell growth and gene expression. Differentially expressed genes (DEGs) were identified for METRO-TOPO therapy and compared to a PCa patient cohort and The Cancer Genome Atlas (TCGA) database. The top five DEGs were SERPINB5, CDKN1A, TNF, FOS, and ANGPT1. Ingenuity Pathway Analysis predicted several upstream regulators and identified top molecular networks associated with METRO dosing, including tumor suppression, anti-proliferation, angiogenesis, invasion, metastasis, and inflammation. Further, the top DEGs were associated with increase survival of PCa patients (TCGA database), as well as ethnic differences in gene expression patterns in patients and cell lines representing African Americans (AA) and European Americans (EA). Thus, we have identified candidate pharmacogenomic biomarkers and novel pathways associated with METRO-TOPO therapy that will serve as a foundation for further investigation and validation of METRO-TOPO as a novel treatment option for prostate cancers.


2007 ◽  
Vol 177 (4S) ◽  
pp. 48-48
Author(s):  
Shintaro Narita ◽  
Norihiko Tsuchiya ◽  
Mitsuru Saito ◽  
Takamitsu Inoue ◽  
Teruaki Kumazawa ◽  
...  

2007 ◽  
Vol 6 (12) ◽  
pp. 1880-1888 ◽  
Author(s):  
Cinzia Antognelli ◽  
Chiara Del Buono ◽  
Francesca Baldracchini ◽  
Vincenzo Talesa ◽  
Emanuele Cottini ◽  
...  

The Prostate ◽  
2009 ◽  
Vol 69 (2) ◽  
pp. 181-190 ◽  
Author(s):  
Suvarna Bhamre ◽  
Debashis Sahoo ◽  
Robert Tibshirani ◽  
David L. Dill ◽  
James D. Brooks

Sign in / Sign up

Export Citation Format

Share Document